| 1 |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| 2 |
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study [J]. Liver Int, 2015, 35(9): 2155-2166.
|
| 3 |
Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma [J]. Biosci Trends, 2021, 15(3): 155-160.
|
| 4 |
Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements [J]. J Hepatol, 2020, 72(2): 288-306.
|
| 5 |
Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage [J]. Vasc Cell, 2014, 6: 18.
|
| 6 |
Dietrich CF, Nolsoe CP, Barr RG, et al. Guidelines and good clinical practice recommendations for contrast-enhanced ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS [J]. Ultrasound Med Biol, 2020, 46(10): 2579-2604.
|
| 7 |
Wildner D, Schellhaas B, Strack D, et al. Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS) [J]. Clin Hemorheol Microcirc, 2019, 71(1): 39-51.
|
| 8 |
Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus [J]. Int J Surg, 2015, 20: 8-16.
|
| 9 |
李红学, 刘军杰, 赵盛发, 等. 超声造影在门脉癌栓诊断和分型中的临床价值 [J]. 吉林大学学报(医学版), 2016, 42(2): 380-384.
|
| 10 |
Nam K, Stanczak M, Lyshchik A, et al. Evaluation of hepatocellular carcinoma transarterial chemoembolization using quantitative analysis of 2D and 3D real-time contrast enhanced ultrasound [J]. Biomed Phys Eng Express, 2018, 4(3): 035039.
|
| 11 |
Wang Y, Xuan Z, Zheng X, et al. Efficacy of endostar combined with transcatheter arterial chemoembolization and analysis of vascular endothelial factor and C-reactive protein levels in patients with advanced hepatocellular carcinoma under contrast enhanced ultrasound [J]. J BUON, 2020, 25(1): 407-414.
|
| 12 |
Brown DB, Nikolic B, Covey AM, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy [J]. J Vasc Interv Radiol, 2012, 23(3): 287-294.
|
| 13 |
Bo J, Peng H, LianHua Z, et al. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol [J]. BMC Cancer, 2021, 21(1): 1171.
|
| 14 |
Liu M, Lin MX, Lu MD, et al. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST [J]. Eur Radiol, 2015, 25(8): 2502-2511.
|
| 15 |
Wessner CE, Shaw CM, Stanczak M, et al. Contrast-enhanced ultrasound identifies patent feeding vessels in transarterial chemoembolization patients with residual tumor vascularity [J]. Ultrasound Q, 2020, 36(3): 218-223.
|
| 16 |
Hai Y, Savsani E, Chong W, et al. Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma [J]. Abdom Radiol (NY), 2021, 46(11): 5162-5179.
|
| 17 |
Watanabe Y, Ogawa M, Kumagawa M, et al. Utility of contrast-enhanced ultrasound for early therapeutic evaluation of hepatocellular carcinoma after transcatheter arterial chemoembolization [J]. J Ultrasound Med, 2020, 39(3): 431-440.
|
| 18 |
Cao J, Dong Y, Fan P, et al. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the role of dynamic three-dimensional contrast-enhanced ultrasound [J]. Clin Hemorheol Microcirc, 2021, 78(4): 365-377.
|
| 19 |
Uller W, Wiggermann P, Gössmann H, et al. Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): Preliminary data [J]. Clin Hemorheol Microcirc, 2011, 49(1-4): 55-66.
|
| 20 |
Shiozawa K, Matsui T, Murakami T, et al. Predicting therapeutic efficacy of transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma using contrast-enhanced ultrasound [J]. Diagnostics (Basel), 2021, 11(2): 291.
|
| 21 |
Moschouris H, Kalokairinou-Motogna M, Vrakas S, et al. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS) [J]. Med Ultrason, 2017, 19(2): 134-142.
|
| 22 |
Paul SB, Dhamija E, Gamanagatti SR, et al. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography [J]. Diagn Interv Imaging, 2017, 98(3): 253-260.
|
| 23 |
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases [J]. Hepatology, 2018, 68(2): 723-750.
|
| 24 |
Eso Y, Marusawa H. Novel approaches for molecular targeted therapy against hepatocellular carcinoma [J]. Hepatol Res, 2018, 48(8): 597-607.
|
| 25 |
Baltzer PAT, Ryu H, Kim JH, et al. Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility [J]. PloS One, 2020, 15(12): e0244304.
|
| 26 |
Zocco MA, Garcovich M, Lupascu A, et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound [J]. J Hepatol, 2013, 59(5): 1014-1021.
|
| 27 |
Frampas E, Lassau N, Zappa M, et al. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results [J]. Eur J Radiol, 2013, 82(5): e205-e211.
|
| 28 |
Kuorda H, Abe T, Fujiwara Y, et al. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma [J]. World J Gastroenterol, 2019, 25(19): 2365-2372.
|
| 29 |
Eso Y, Nakano S, Mishima M, et al. A simplified method to quantitatively predict the effect of lenvatinib on hepatocellular carcinoma using contrast-enhanced ultrasound with perfluorobutane microbubbles [J]. Quant Imaging Med Surg, 2021, 11(6): 2766-2774.
|
| 30 |
Kamachi N, Nakano M, Okamura S, et al. Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound [J]. Cancer Rep (Hoboken), 2022, 5(2): e1471.
|
| 31 |
Roskoski RJr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas [J]. Pharmacol Res, 2017, 120: 116-132.
|
| 32 |
仲康, 张亦青, 陈华. 原发性肝细胞癌抗血管生成治疗后血管内皮生长因子及血流灌注参数变化 [J]. 世界华人消化杂志, 2019, 27(12): 786-790.
|
| 33 |
Jiang Y, Chen M, Nie H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations [J]. Hum Vaccin Immunother, 2019, 15(5): 1111-1122.
|
| 34 |
Uhlig J, Stein S, Kim HS. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA [J]. Future Oncol, 2022, 18(14): 1691-1703.
|
| 35 |
Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial [J]. J Clin Oncol, 2022, 40(2): 150-160.
|
| 36 |
Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma [J]. J Clin Oncol, 2020, 38(26): 2960-2970.
|
| 37 |
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial [J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
|
| 38 |
Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma [J]. Front Oncol, 2021, 11: 618206.
|
| 39 |
Fei X, Han P, Jiang B, et al. High frame rate contrast-enhanced ultrasound helps differentiate malignant and benign focal liver lesions [J]. J Clin Transl Hepatol, 2022, 10(1): 26-33.
|
| 40 |
Jung EM, Moran VO, Engel M, et al. Modified contrast-enhanced ultrasonography with the new high-resolution examination technique of high frame rate contrast-enhanced ultrasound (HiFR-CEUS) for characterization of liver lesions: first results [J]. Clin Hemorheol Microcirc, 2023, 83(1): 31-46.
|
| 41 |
Jiang ZZ, Huang YH, Shen HL, et al. Clinical applications of superb microvascular imaging in the liver, breast, thyroid, skeletal muscle, and carotid plaques [J]. J Ultrasound Med, 2019, 38(11): 2811-2820.
|
| 42 |
Murakami K, Kasajima A, Kawagishi N, et al. Microvessel density in hepatocellular carcinoma: prognostic significance and review of the previous published work [J]. Hepatol Res, 2015, 45(12): 1185-1194.
|
| 43 |
Mandai M, Koda M, Matono T, et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT [J]. Br J Radiol, 2011, 84(1002): 499-507.
|
| 44 |
Kan M, Hiraoka A, Uehara T, et al. Evaluation of contrast-enhanced ultrasonography using perfluorobutane (Sonazoid((R))) in patients with small hepatocellular carcinoma: comparison with dynamic computed tomography [J]. Oncol Lett, 2010, 1(3): 485-488.
|
| 45 |
Ahn SJ, Lee JM, Lee DH, et al. Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma [J]. J Hepatol, 2017, 66(2): 347-354.
|
| 46 |
Minami Y, Kudo M. Image guidance in ablation for hepatocellular carcinoma: contrast-enhanced ultrasound and fusion imaging [J]. Front Oncol, 2021, 11: 593636.
|
| 47 |
张兆辉, 庄轶超, 杨文宪, 等. 瞬时弹性成像技术对原发性胆汁性肝硬化、自身免疫性肝炎的鉴别及与肝脏纤维化程度、肝功能的相关性研究 [J]. 世界华人消化杂志, 2023, 31(11): 464-469.
|